New allergy vaccine on track for pivotal trial phase

26 January 2017
biomay-big

Privately-owned Austrian company Biomay has announced positive results from a Phase IIb study into its grass pollen allergy vaccine BM32.

BM32 is an investigational grass pollen allergy vaccine based on an innovative kind of technology which the company believes has the potential to create a “paradigm shift” in the treatment of allergies.

The immunotherapeutics specialists stated that the study reached its primary endpoint and showed that a regimen of five monthly injections of BM32 produced a clinically superior outcome to other dosing schemes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical